Stryker (NYSE:SYK) Given New $340.00 Price Target at Truist Financial

Stryker (NYSE:SYK) had its price target upped by equities researchers at Truist Financial from $330.00 to $340.00 in a research report issued on Friday,Benzinga reports. The firm currently has a “hold” rating on the medical technology company’s stock. Truist Financial’s target price points to a potential upside of 5.85% from the stock’s current price.

Several other brokerages have also recently issued reports on SYK. Citigroup dropped their target price on Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a research report on Tuesday, April 7th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $361.00 price objective on shares of Stryker in a research note on Friday, May 1st. Leerink Partners cut their price target on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research note on Friday, June 5th. Weiss Ratings cut shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 4th. Finally, UBS Group started coverage on Stryker in a research note on Tuesday. They set a “buy” rating and a $400.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $392.50.

Stryker Price Performance

Shares of NYSE:SYK opened at $321.22 on Friday. Stryker has a 1-year low of $281.00 and a 1-year high of $401.99. The business has a fifty day moving average price of $317.08 and a 200-day moving average price of $334.98. The company has a market capitalization of $123.14 billion, a PE ratio of 37.44, a PEG ratio of 2.26 and a beta of 0.77. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business’s revenue was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities analysts expect that Stryker will post 14.99 EPS for the current fiscal year.

Insider Activity at Stryker

In related news, VP M Kathryn Fink sold 3,500 shares of the stock in a transaction on Monday, May 11th. The stock was sold at an average price of $283.45, for a total value of $992,075.00. Following the transaction, the vice president owned 177 shares of the company’s stock, valued at $50,170.65. This represents a 95.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 323,264 shares of company stock valued at $100,659,489 over the last 90 days. 4.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Stryker

Hedge funds have recently modified their holdings of the stock. Brighton Jones LLC boosted its stake in shares of Stryker by 15.4% during the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after acquiring an additional 609 shares in the last quarter. Schnieders Capital Management LLC. purchased a new stake in shares of Stryker in the second quarter valued at $205,000. Marshall Wace LLP lifted its position in Stryker by 107.9% during the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock worth $2,255,000 after buying an additional 77,831 shares during the period. Nebula Research & Development LLC purchased a new stake in Stryker in the 2nd quarter valued at about $219,000. Finally, HUB Investment Partners LLC acquired a new stake in shares of Stryker in the second quarter worth approximately $253,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker News Summary

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker reported second-quarter adjusted EPS of $3.69, ahead of the $3.49 consensus estimate and up 17.9% year over year. Revenue rose 9.4% to $6.59 billion, broadly matching expectations, as demand remained strong for orthopedic, spinal and other medical devices. Reuters earnings article
• Positive Sentiment: Management reported 9% organic sales growth, a 66% adjusted gross margin and progress recovering from the March cyberattack. The company also resumed share repurchases, potentially supporting earnings and shareholder returns. MassDevice cyberattack recovery article
• Positive Sentiment: Stryker reaffirmed a strong 2026 outlook, forecasting 8.3%-9.3% organic sales growth and adjusted EPS of $14.95-$15.10. The midpoint is generally in line with Wall Street expectations, while the narrowed range signals improved visibility. Stryker 2026 outlook article
• Neutral Sentiment: UBS initiated research coverage on Stryker, adding another institutional view, although the initial rating and target were not provided in the available report. UBS coverage article
• Negative Sentiment: BTIG Research lowered its price target from $371 to $358, leaving only limited implied upside, although it maintained a Buy rating. The reduced target may weigh on sentiment, particularly with Stryker trading at roughly 40 times earnings. BTIG price target article
• Negative Sentiment: Despite the EPS beat, the stock declined after quarterly sales came in essentially in line with estimates. Investors may also remain concerned about lingering operational effects and costs from the cyberattack, as well as the premium valuation.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.